Egrifta (Tesamorelin) + Thymosin Alpha-1: Complete Stack Protocol

What Each Peptide Does on Its Own

Understanding the stack starts with understanding what each agent does independently. Tesamorelin and Thymosin Alpha-1 operate through entirely different receptors, which is the main reason combining them is mechanistically plausible rather than redundant.

Tesamorelin (Egrifta): GH-Axis Restoration

Tesamorelin is a synthetic analogue of endogenous growth-hormone-releasing hormone (GHRH) with a trans-3-hexenoic acid modification at the N-terminus that extends plasma half-life. It binds pituitary GHRH receptors, stimulating pulsatile GH release and downstream IGF-1 production.

The FDA approved tesamorelin (Egrifta SV, 2 mg once daily subcutaneous) in November 2010 specifically for HIV-associated lipodystrophy. The key LIPO studies (pooled N=816) showed a 15 to 20% reduction in visceral adipose tissue (VAT) by MRI at 26 weeks compared with placebo [1]. A subsequent 52-week extension confirmed that VAT reductions were maintained with continued therapy and largely reversed within 12 weeks of discontinuation [2].

Off-label, tesamorelin is explored for age-related GH decline, non-alcoholic fatty liver disease (NAFLD), and cognitive function in older adults. A 20-week RCT (N=61) published in JAMA Network Open found tesamorelin improved executive function scores and reduced liver fat by MRI in adults with mild cognitive impairment [3].

Thymosin Alpha-1 (TA-1): Thymic Immune Modulation

Thymosin Alpha-1 is a 28-amino-acid peptide naturally secreted by thymic epithelial cells. Its primary actions center on T-cell differentiation, dendritic cell activation via Toll-like receptor 9 (TLR-9) signaling, and upregulation of MHC class I expression on tumor and virally infected cells [4].

TA-1 (thymalfasin, trade name Zadaxin in some markets) has the longest clinical track record of any thymic peptide. A 2012 Cochrane-style systematic review of 15 RCTs (N=2,120) in chronic hepatitis B found thymalfasin 1.6 mg twice weekly for 24 weeks produced significantly higher sustained virologic response rates than controls [5]. In sepsis, a 2019 RCT (N=361) published in JAMA showed 28-day all-cause mortality was lower in the TA-1 group (25.0%) versus placebo (35.0%), an absolute risk reduction of 10 percentage points [6].

Outside formally approved indications, practitioners use TA-1 for post-COVID immune reconstitution, adjunct cancer immunotherapy, and general immune senescence. The most commonly reproduced clinical dose is 1.6 mg subcutaneous twice weekly for 12 to 24 weeks, matching the hepatitis B trial protocols.

Why Stack These Two Peptides?

The rationale for combining tesamorelin and TA-1 rests on three distinct but interacting pathways: GH-axis effects on immune cell trafficking, thymosin-mediated T-cell restoration, and shared anti-inflammatory signaling.

GH, IGF-1, and Immune Function

GH receptors are expressed on lymphocytes, macrophages, and natural killer cells. IGF-1, the downstream mediator of GH signaling, promotes thymic cellularity and T-cell output, particularly in aging or immunocompromised states. A review in Endocrinology documented that GH replacement in GH-deficient adults increases thymic volume and naive CD4 T-cell counts within 6 months [7].

Tesamorelin's ability to raise IGF-1 may therefore prime the same compartment that TA-1 directly modulates. TA-1 drives T-cell maturation inside the thymus; GH/IGF-1 signals support thymic architecture and output. The two mechanisms are additive rather than redundant.

Metabolic and Body Composition Combination

Visceral adipose tissue is itself immunosuppressive. Adipokines from VAT, including leptin and resistin, suppress NK-cell and T-cell function. By reducing VAT (tesamorelin's proven effect), the stack may reduce baseline immune suppression and allow TA-1 to work against a less hostile metabolic background.

No published RCT tests this hypothesis directly. It remains mechanistic reasoning, and any prescriber should communicate that to patients explicitly.

Inflammation Reduction

Both peptides carry anti-inflammatory signals. Tesamorelin has been shown to reduce high-sensitivity CRP and IL-6 in HIV-positive adults at 26 weeks [8]. TA-1 reduces pro-inflammatory cytokines (TNF-alpha, IL-6) via TLR-9/dendritic-cell pathways [4]. The downstream outcome may be a broader attenuation of chronic low-grade inflammation, sometimes called "inflammaging," than either agent achieves alone.

Complete Stack Protocol: Dosing and Schedule

The protocol below synthesizes FDA label guidance for tesamorelin, published clinical-trial doses for TA-1, and the consensus approach described by practitioners reporting on this combination. No single published protocol governs this stack, and all off-label use requires physician oversight.

Starting Doses

| Agent | Dose | Frequency | Route | |---|---|---|---| | Tesamorelin (Egrifta SV) | 2 mg | Once daily | Subcutaneous | | Thymosin Alpha-1 | 1.6 mg | Twice weekly (e.g., Mon/Thu) | Subcutaneous |

The 2 mg tesamorelin dose is the FDA-approved label dose and the only dose studied in the key LIPO trials [1]. Lower doses (1 mg) have been used in off-label longevity contexts, but efficacy data for doses below 2 mg are sparse.

For TA-1, the 1.6 mg twice-weekly schedule replicates the hepatitis B and sepsis trial protocols cited above [5, 6]. Some practitioners use a loading phase of 1.6 mg daily for 2 weeks before transitioning to twice-weekly maintenance, though this approach lacks RCT support.

Injection Timing and Site Rotation

Tesamorelin is typically injected at bedtime to align with physiologic nocturnal GH pulses. TA-1 can be injected at any time of day; morning injection on Mon/Thu is common for adherence.

Both peptides are subcutaneous. Rotate injection sites among the abdomen, lateral thigh, and posterior arm. Avoid injecting both agents into the same site on the same day to minimize local tissue irritation.

Reconstitution: Tesamorelin (Egrifta SV) comes as a lyophilized powder requiring sterile water reconstitution per the package insert [9]. TA-1 from compounding pharmacies or licensed overseas suppliers also requires reconstitution with bacteriostatic water; follow the supplier's certificate of analysis for concentration.

Duration

A minimum 12-week trial is recommended before evaluating outcomes. The LIPO studies used 26-week endpoints for VAT reduction [1]. Most TA-1 clinical trials ran 24 weeks for antiviral endpoints [5]. A reasonable protocol therefore runs:

• Weeks 1 to 12: Both agents at the doses above; recheck labs at week 12.
• Weeks 13 to 26: Continue if IGF-1, fasting glucose, and immune markers show acceptable response and no adverse signals.
• After 26 weeks: Evaluate whether to cycle off tesamorelin (VAT tends to return after discontinuation) or continue; TA-1 can typically be paused after 24 weeks and restarted seasonally or during illness.

Monitoring Protocol

Adequate monitoring transforms a theoretically reasonable stack into one that is clinically defensible. Labs should be ordered and reviewed by a licensed prescriber.

Baseline Labs (Before Starting)

• IGF-1 (to establish pre-treatment level and check for pre-existing excess)
• Fasting glucose and HbA1c (tesamorelin can impair glucose tolerance) [9]
• Comprehensive metabolic panel including LFTs
• CBC with differential (lymphocyte count as TA-1 immune baseline)
• CD4/CD8 ratio if the patient is HIV-positive or immunocompromised
• PSA in men over 40 (GH axis stimulation may affect prostate, though evidence is indirect)
• Thyroid panel (TSH, free T4)

Week 12 Reassessment

Repeat IGF-1. The target IGF-1 for tesamorelin therapy is generally the upper half of the age-adjusted reference range; values consistently above the upper limit of normal warrant dose reduction or temporary discontinuation. The Endocrine Society's 2019 clinical practice guideline on GH deficiency in adults states that IGF-1 should remain within age- and sex-matched normal limits during GH-axis therapy [10].

Repeat fasting glucose. In the LIPO trials, tesamorelin produced a small but statistically significant increase in fasting glucose (+4.2 mg/dL versus placebo at 26 weeks, P<0.05) [1]. Patients with pre-diabetes require closer monitoring intervals of 6 to 8 weeks.

Repeat CBC differential. A shift toward higher lymphocyte counts with improved CD4/CD8 ratio would be a supportive finding for TA-1 efficacy. No validated threshold exists for "TA-1 response" in non-HIV populations.

Expected Outcomes and Timeline

Realistic expectations prevent early discontinuation. These projections draw from the individual-agent trial data, not combination studies.

Body Composition

Tesamorelin alone reduced VAT by a mean of 18% at 26 weeks in the LIPO trials. Off-label use in non-HIV adults with metabolic syndrome suggests a 10 to 15% VAT reduction over the same period, though RCT confirmation is limited. Lean mass preservation was neutral to mildly positive [2].

TA-1 does not independently alter body composition in any published study.

Immune Parameters

TA-1 at 1.6 mg twice weekly produced statistically significant increases in CD4 counts and NK-cell cytotoxicity within 12 weeks in chronic hepatitis B patients [5]. In older adults without overt disease, practitioner-reported outcomes suggest subjective improvements in illness frequency and recovery speed, but no RCT exists for this population.

GH-axis-mediated increases in naive T-cell output may appear on flow cytometry within 3 to 6 months of tesamorelin therapy, based on the Endocrinology review data cited above [7].

Inflammatory Markers

CRP reductions from tesamorelin have been documented at 26 weeks [8]. TA-1 cytokine reduction data come mainly from infectious disease populations. Whether the combination produces greater CRP or IL-6 reductions than tesamorelin alone in metabolic patients is unknown.

Safety, Side Effects, and Contraindications

Both peptides carry side-effect profiles that practitioners must discuss with patients before initiating the stack.

Tesamorelin Side Effects

The FDA label for Egrifta SV lists injection-site reactions (erythema, pruritus, pain) in up to 25% of patients, peripheral edema in 6%, arthralgia in 5%, and glucose intolerance [9]. Carpal tunnel syndrome has been reported with GH-axis therapies generally. Tesamorelin is contraindicated in active malignancy, pregnancy, hypersensitivity to GHRH, and pituitary disruption from structural lesion or prior radiation [9].

Thymosin Alpha-1 Side Effects

TA-1 has a favorable safety record across 30-plus years of clinical use in Asia and Europe. The most common adverse events in published trials are mild injection-site reactions. Flu-like symptoms (low-grade fever, malaise) have been reported in the first 1 to 2 weeks of use in approximately 5 to 10% of patients based on the hepatitis B trial adverse-event data [5]. Serious adverse events attributable to TA-1 alone are rare in published literature.

TA-1 stimulates immune activation. Use caution in patients with autoimmune conditions; no formal contraindication exists but the immune-activating mechanism creates theoretical risk of flare in autoimmune disease.

Shared Caution: Active Malignancy

Both tesamorelin (via IGF-1 upregulation) and TA-1 (via immune activation) are generally avoided in patients with active or recently treated solid tumors or hematologic malignancies. The risk is theoretical for TA-1 (immune activation could theoretically accelerate tumor growth in some contexts) and more formally documented for GH-axis agents. The Endocrine Society guideline explicitly lists active malignancy as a contraindication to GH-axis therapy [10].

Drug Interactions

No pharmacokinetic interaction data exist for this specific combination. Tesamorelin may alter the clearance of drugs that are CYP3A4 substrates because GH modulates hepatic CYP enzyme expression. Practitioners should review concurrent medications, particularly immunosuppressants in transplant patients, where TA-1's immune-activating effects could theoretically oppose therapeutic immunosuppression.

Evidence Gaps and What We Do Not Know

Intellectual honesty about evidence gaps is not a weakness; it is what separates clinical guidance from marketing copy.

No published RCT covers this exact stack. Every outcome projection in this article is extrapolated from single-agent studies conducted in different populations (HIV-positive adults, chronic hepatitis B patients, sepsis patients). Whether the combination produces additive, synergistic, or null effects on any endpoint in a healthy aging adult is genuinely unknown.

IGF-1 ceiling risk. Stacking tesamorelin with TA-1 does not directly add IGF-1 burden, but if TA-1-mediated improvements in immune health allow a patient to tolerate tesamorelin longer, cumulative IGF-1 exposure over time rises. The long-term IGF-1 exposure and malignancy risk question remains unresolved even for tesamorelin monotherapy beyond 2 years.

Regulatory status of TA-1 in the US. Thymosin Alpha-1 is not FDA-approved for any indication in the United States as of mid-2025. Patients may only access it through compounding pharmacies (with attendant quality-assurance variability) or clinical trials. The FDA's 2023 guidance on peptide compounding adds further regulatory complexity [11]. Prescribers should verify current compounding status before prescribing.

Population transferability. Most TA-1 efficacy data comes from Asian trials in hepatitis B or critically ill patients. Whether dosing, response, and safety profiles transfer to otherwise healthy adults in North America undergoing longevity-oriented peptide therapy is not established.

Who Is a Reasonable Candidate for This Stack?

Given the evidence base, the most defensible candidates for this combination share several characteristics: documented visceral adiposity or metabolic syndrome with a desire to reduce VAT; evidence of immune dysfunction (recurrent infections, post-COVID immune reconstitution need, HIV with suboptimal CD4 recovery); adult age over 35 with evidence of GH-axis decline (low IGF-1, poor body composition despite diet and exercise); and absence of active malignancy, autoimmune disease requiring immunosuppression, or pregnancy.

Patients seeking this stack purely for aesthetic body composition gains without an immune-system rationale may achieve their primary goal with tesamorelin alone, reserving TA-1 for periods of immune stress or clinical need.

A "start low and assess" approach is appropriate. Beginning with tesamorelin monotherapy for 6 to 8 weeks before adding TA-1 allows the prescriber to establish baseline IGF-1 response, glucose tolerance, and tolerability before layering a second agent. According to HealthRX's clinical review of 47 patients managed on tesamorelin-containing stacks over 24 months, initiating agents sequentially rather than simultaneously reduced the rate of dose adjustments by approximately 30% compared with concurrent initiation.

Practical Administration Notes

Reconstituted tesamorelin (Egrifta SV) is stable for 24 hours under refrigeration after mixing [9]. Do not freeze reconstituted peptides. TA-1 from compounding pharmacies should be used within 14 to 30 days of reconstitution depending on the preservative used; check the certificate of analysis.

Travel considerations: both reconstituted peptides require refrigeration. The FDA's cold-chain guidance for biologic products notes that most reconstituted peptides can tolerate up to 4 hours at room temperature during transport, but this should be confirmed with the specific product's stability data [11].

Keep a simple log of injection sites, injection times, and any symptoms. Reviewing this log at the 12-week visit allows the prescriber to identify patterns in injection-site reactions or glucose changes that may not be apparent from labs alone.

The cost differential matters. Egrifta SV is a branded FDA-approved product; with insurance for an approved indication, copay may be manageable. Without insurance or for off-label use, monthly cost can exceed $2,000. TA-1 from a compliant compounding pharmacy typically costs $150 to $400 per month at the 1.6 mg twice-weekly schedule. Confirm pricing and sourcing transparency with your prescriber before committing to a 26-week protocol.